On April 1, 2022 Novocure (NASDAQ: NVCR) reported that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open (Press release, NovoCure, APR 1, 2022, View Source [SID1234611358]). Novocure’s management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2022, at 8 a.m. EDT on Thursday, April 28, 2022. Analysts and investors can participate in the conference call by dialing 855-442-6895 for domestic callers and 509-960-9037 for international callers, using the conference ID 1476184.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

On April 1, 2022 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that it is scheduled to participate in the following upcoming events (Press release, Arrowhead Pharmaceuticals, APR 1, 2022, View Source [SID1234611357]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022) – March 30-April 3, 2022

Title: Pharmacokinetics and Safety of JNJ-73763989, an RNA Interference Therapy for Hepatitis B Virus, in Moderately Hepatically Impaired Participants
Authors: Thomas N. Kakuda, et al.

Title: Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants
Authors: Haiyan Li, et al.

Title: Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Authors: Edward Gane, et al.

American Association for Cancer Research Annual Meeting 2022 (AACR) (Free AACR Whitepaper) – April 8-13, 2022

Title: Targeting HIF2a with siRNA: From preclinical models to the clinic
Authors: Yuanqing Ma, et al.

DIA/FDA’s Oligonucleotide-based Therapeutics Conference (Oligo22) – April 25-27, 2022

Title: Short Interfering RNA JNJ-3989 Combination Therapy
Presenter: Michael Biermer, Senior Director, Clinical Development, Janssen Pharmaceuticals

Title: ARO-HIF2 Evaluated in Clear Cell Renal Cell Carcinoma Ph1b Clinical Trial
Presenter: James Hamilton, Senior Vice President, Discovery and Translational Medicine, Arrowhead Pharmaceuticals

A copy of the presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

On April 1, 2022 Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, reported a two-day summit hosted by the B. Riley Securities’ Healthcare Equity Research team, that will feature multiple programs from Fortress’ diversified pipeline (Press release, Fortress Biotech, APR 1, 2022, View Source [SID1234611356]). The events will be held virtually on Tuesday, April 5, and Wednesday, April 6, 2022, beginning at 1:00 p.m. ET each day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Registration link and webcast information:

Please click here to register for the event.
Following each event, the webcast will be available on the News / Events page, located within the Investors section of Fortress’ website, View Source, for approximately 30 days.
Agenda:

Day One: Tuesday, April 5, 2022 (1:00 p.m. – 3:00 p.m. ET)

1:00 p.m. ET – Opening Remarks and Fortress Strategy

Lindsay Rosenwald, M.D., Chairman, President & Chief Executive Officer of Fortress Biotech; Mayank Mamtani, Head of HC Research, B. Riley Securities

1:30 p.m. ET – Panel #1 – Journey Medical Corporation (NASDAQ: DERM)

Claude Maraoui, Co-Founder, President & Chief Executive Officer; Ernie De Paolantonio, Chief Financial Officer; Ramsey Alloush, General Counsel

2:00 p.m. ET – Panel #2 – Cyprium Therapeutics

Charles Buchen, M.D., Chief Business Officer; Lung Yam, M.D., Ph.D., President & Chief Scientific Officer

2:30 p.m. ET – Panel #3 – UR-1 Therapeutics

Raymond Zheng, Ph.D., President & Chief Scientific Officer; Scott Baumgartner, M.D., Interim Chief Medical Officer

Day Two: Wednesday, April 6, 2022 (1:00 p.m. – 3:00 p.m. ET)

1:00 p.m. ET – Fortress Strategy – Execution and Value Generation

Lindsay Rosenwald, M.D., Chairman, President & Chief Executive Officer of Fortress Biotech

1:30 p.m. ET – Panel #1 – Mustang Bio (NASDAQ: MBIO)

Manuel Litchman, M.D., President & Chief Executive Officer; Knut Niss, Ph.D., Chief Technology Officer; Bruce Dezube, M.D., Senior Vice President, Head of Clinical Development; Eliot Lurier, C.P.A., Interim Chief Financial Officer

2:15 p.m. ET – Panel #2 – Checkpoint Therapeutics (NASDAQ: CKPT)

James F. Oliviero, President & Chief Executive Officer; Garrett Gray, Chief Financial Officer

On April 1, 2022 Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, reported the company reported a cash position of $56.9 million as of December 31, 2021 during its earnings announcement on March 31, 2022 (Press release, Celsion, APR 1, 2022, View Source [SID1234611353]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A transcript issued by SeekingAlpha erroneously originally quoted the Company’s cash position of $15 million. The transcript has since been corrected.

"We reported a cash position of $56.9 million as of December 31, 2021. Subsequent to the end of the quarter, we received $1.4 million in non-dilutive funding from the sale of our New Jersey State net operating losses, adding to our cash at year end." said Jeffrey Church, Chief Financial Officer at Celsion.

Michael H. Tardugno, chairman, president and chief executive officer of Celsion, noted "Our company is in a very strong cash position with capital resources sufficient to support our strategic plans and development through the end of 2024 at current spending projections. We remain optimistic about our TheraPlas and PLACCINE development programs, with GEN-1 patient enrollment now over 80% and full enrollment anticipated in the third quarter of 2022 and our DNA-based vaccine targeting the SARS-Co-V-2 virus moving forward with non-human primate studies this quarter. 2022 should be an exciting year for us, and we are looking forward to several important milestones throughout the year."

On April 1, 2022 GlaxoSmithKline plc ("GSK") reported its financial reporting under regular review to ensure that it remains current and in line with both the latest regulatory requirements and developing best practice within the Pharmaceutical industry (Press release, GlaxoSmithKline, APR 1, 2022, View Source [SID1234611352]).

Revised reporting segments for Pharmaceuticals and Vaccines
GSK announced at the Investor Update on 23 June 2021 that revised reporting segments for new GSK would be presented from the first quarter 2022 results. The new operating segments are reported based on the financial information provided to the Chief Executive Officer and the responsibilities of the GSK Leadership Team (GLT).
Previously, GSK reported results under four segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. From the first quarter 2022 results GSK will report results under three segments on the following basis:
● The Commercial Operations segment includes the results that were previously reported under the Pharmaceuticals segment and the Vaccines segment but now excludes expenditure related to research & development included in the segment below. This change reflects the closer integration and management of the commercial,
manufacturing and other operations of the Pharmaceutical and Vaccines portfolio. The Commercial Operations segment continues to include the ViiV Healthcare commercial operating profit. The research and development managed expenditure related to ViiV Healthcare (previously reported within the Pharmaceuticals segment) and
Vaccines (previously reported within the Vaccines segment) will be reported as part of the Research and Development segment. The Commercial Operations segment will also include the Group’s global health initiatives that were previously separately reported through the Pharmaceuticals R&D and Vaccines segments as well as within
Corporate and other unallocated costs;
● The Research and Development segment includes the costs previously reported under the Pharmaceuticals R&D segment. The segment will also include the research and development managed expenditure related to ViiV Healthcare (previously reported within the Pharmaceuticals segment) and Vaccines (previously reported within the
Vaccines segment). The new segment reflects the changes that have been made to the management of research, development and other related costs (such as regulatory and administration costs) through the "One R&D" organisational changes. The Research and Development segment now excludes costs related to the Group’s global health
initiatives;
● The Consumer Healthcare segment will be reported as a "Continuing operation" operating segment until such time as the formal criteria for treating Consumer Healthcare as a ‘Discontinued operation’ have been satisfied (currently expected in Q2 2022). We will consolidate the business for reporting purposes until the demerger has
completed.

Corporate and other unallocated costs include the costs of corporate functions that are not managed by and are not the responsibility of the operating segments.
The revised segment turnover and operating profit tables below set out the new operating segments that will be used from the first quarter 2022 results, as applied to the 2021 quarterly reported turnover and profits.

Product sales to be reported within three product groups – Specialty Medicines, General Medicines and Vaccines
GSK will report product sales within three product groups from the first quarter 2022 results:
● Specialty Medicines products will include GSK’s marketed products for HIV, oncology, immuno-inflammation, respiratory and other specialty medicines (including Nucala) and the pandemic solution, Xevudy;
● General Medicines products, which include products previously reported as Established Pharmaceuticals and sales of Trelegy Ellipta and Anoro Ellipta (previously reported within the Respiratory category under Specialty products). These products are typically accessed by patients through primary care settings;
● Vaccines products, including sales of GSK’s AS03 adjuvant as part of the pandemic solutions.

Disclosure of Consumer Healthcare category for brands divested and under review to be removed
Following the completion of the Consumer Healthcare brand divestment programme in the first quarter 2021, the sales of the remaining products that were reported under the brands divested and under review category and which have not been divested will be reported under their original category again from the first quarter 2022 results. In addition, the sales of the brands divested in the first quarter 2021 will also not be reported in the separate brands divested category for the comparative periods of 2021.

As a result of these changes, from the first quarter 2022 the presentation of a separate category for brands divested and under review will no longer be required.

The revised turnover tables below set out the revised format for reporting sales that will be used from the first quarter 2022 results, as applied to the 2021 quarterly reported product sales.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!